Who are verteporfin PDT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Verteporfin Photodynamic Therapy, Verteporfin for injection, Levulan® Kerastick®, Methyl Aminolaevulinate 16% Cream, MAL, Visudyne for injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/verteporfin-pdt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

verteporfin PDT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

verteporfin PDT (verteporfin PDT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Photosensitizing agent. Area: Ophthalmology.

marketed Photosensitizing agent Lipoprotein receptors on neovascular endothelial cells Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

verteporfin PDT (verteporfin PDT) — QLT Inc.. Verteporfin is a photosensitizing agent that accumulates in abnormal blood vessels and is activated by light to generate reactive oxygen species that destroy those vessels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
verteporfin PDT TARGET	verteporfin PDT	QLT Inc.	marketed	Photosensitizing agent	Lipoprotein receptors on neovascular endothelial cells
Verteporfin Photodynamic Therapy	Verteporfin Photodynamic Therapy	Novartis	marketed	Photosensitizing agent	Lipoprotein receptors on neovascular endothelial cells
Verteporfin for injection	Verteporfin for injection	Novartis	marketed	Photosensitizing agent	Lipoprotein receptors on neovascular endothelial cells
Levulan® Kerastick®	Levulan® Kerastick®	Medical Dermatology Specialists	marketed	Photosensitizing agent	Protoporphyrin IX (photodynamic therapy precursor)
Methyl Aminolaevulinate 16% Cream	Methyl Aminolaevulinate 16% Cream	Galderma R&D	marketed	Photosensitizing agent	Protoporphyrin IX (via aminolaevulinic acid pathway)
MAL	MAL	Photocure	marketed	Photosensitizing agent	Protoporphyrin IX (via aminolevulinic acid pathway)
Visudyne for injection	Visudyne for injection	QLT Inc.	phase 3	Photosensitizing agent	Lipoprotein and abnormal vasculature (non-selective)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Photosensitizing agent class)

Galderma R&D · 4 drugs in this class
Novartis · 2 drugs in this class
QLT Inc. · 2 drugs in this class
Medical Dermatology Specialists · 1 drug in this class
Photocure · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). verteporfin PDT — Competitive Intelligence Brief. https://druglandscape.com/ci/verteporfin-pdt. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing